GHK-Cu is a three-amino-acid peptide (glycine, histidine, lysine) bound to a copper ion. It occurs naturally in the body and has been studied for skin and wound repair for more than three decades. Most of what you read about it comes from cell and animal research.
The human evidence is thin. A 2026 systematic evidence review concluded that GHK-Cu "should be regarded as a promising but unproven therapeutic cargo rather than a clinically validated regenerative drug." Topical copper peptide skincare is sold as a cosmetic, which FDA does not approve before sale. Injectable GHK-Cu is a different question: no approved drug contains it, and FDA has listed specific safety concerns about compounded injectable versions.
This PeptIQ.io guide explains what GHK-Cu is, how topical and injectable use differ, what the human studies actually found, and where FDA stands as of October 2026. It contains no dosing information and no sources to buy from. Talk to a licensed clinician before using any peptide.
What GHK-Cu Is
GHK is short for glycyl-L-histidyl-L-lysine, a tripeptide. It binds copper(II), and the copper complex is what most products and papers mean by GHK-Cu. On cosmetic labels you may see it listed as copper tripeptide-1.
The most widely cited reviews come from Loren Pickart and colleagues. A 2018 review in the International Journal of Molecular Sciences says GHK "stimulates blood vessel and nerve outgrowth, increases collagen, elastin, and glycosaminoglycan synthesis, as well as supports the function of dermal fibroblasts," and links it to gene-expression changes across many pathways. Two caveats matter. Those findings are mostly from cell, tissue and animal models. And the authors' listed affiliation is a skin-care R&D company, which is worth knowing when you weigh the framing.
GHK-Cu is not collagen. It is a signaling peptide studied for its effects on the cells that make collagen. PeptIQ.io's collagen peptides vs research peptides guide covers that confusion in detail.
Skin vs Injectable: Two Different Questions
Online, "GHK-Cu" covers two very different products. A serum you apply to your face and a vial meant for injection share a name. They do not share a regulatory path, an evidence base or a risk profile.
01 / Skin vs injectable
One name, two very different products
Evidence from a face serum does not transfer to a vial meant for injection. The regulatory path, the data and the risks all change with the route.
Topical skincare
Applied to skin
Sold as
Cosmetic serum or cream (copper tripeptide-1)
FDA review before sale
Not required for cosmetics
Human evidence
Small cosmetic studies, mixed results
FDA concerns on record
None specific to GHK-Cu
Compounding status
Category 1: under evaluation
Who to ask
Dermatologist
Injectable GHK-Cu
Injected under the skin
Sold as
Compounded preparation or “research use only” vial
FDA review before sale
No approved product exists
Human evidence
No controlled human efficacy trials
FDA concerns on record
Immunogenicity from aggregation and impurities; limited human data
Compounding status
Nomination withdrawn
Who to ask
Prescribing clinician or pharmacist
Same molecule name, different products. Sources: FDA cosmetics authority page; FDA 503A bulk drug substances list (updated May 14, 2026); FDA safety-risk page for bulk drug substances (current as of April 22, 2026). Not legal advice.
Topical copper peptide skincare
Creams and serums with copper peptides are generally sold as cosmetics. FDA's cosmetics authority page is explicit: "cosmetic products and ingredients do not need FDA premarket approval, with the exception of color additives." The same page explains that intended use decides the category. A product meant for "beautifying, promoting attractiveness, or altering the appearance" is a cosmetic. A product intended "to affect the structure or function of the body" is a drug. So a copper peptide serum is legal to sell as a cosmetic, but that does not mean FDA has reviewed whether it works.
Injectable GHK-Cu
There is no FDA-approved injectable GHK-Cu. A search of FDA's Drugs@FDA data through openFDA returns no approved product containing it. Injectable GHK-Cu reaches people in two ways: as a compounded preparation from a pharmacy, which is now restricted (see the FDA section below), or as a "research use only" vial, which has no regulatory oversight at all.
FDA's page on bulk drug substances that may present significant safety risks lists GHK-Cu for injectable routes and states that compounded injectable versions "may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities," adding: "There are limited data in humans to inform safety-related considerations." Immunogenicity means the risk of an unwanted immune reaction to the product.
The practical point: topical research does not transfer to injection. A cream study tells you nothing about what happens when the same peptide is injected, which is the use most social media posts are promoting.
What the Human Evidence Actually Shows
The research pyramid for GHK-Cu is wide at the bottom and almost empty at the top.
02 / Evidence ladder
Strong in the lab, thin in people
The higher the rung, the more it tells you about real outcomes in humans. GHK-Cu’s evidence is concentrated on the bottom two.
05
FDA-approved drug
No approved product contains GHK-Cu.
None
04
Controlled wound trials
1992 venous ulcer trial: copper tripeptide cream no different from placebo. 2026 Phase 2 gel trial recruiting, no results.
No benefit shown yet
03
Small cosmetic studies
13-patient laser study negative on objective measures; small 2026 eyebrow study positive but loosely characterized.
Small, mixed
02
Animal studies
Repair, angiogenesis and inflammation effects reported across models.
Consistent signals
01
Cell and tissue studies
Collagen, elastin and fibroblast effects; broad gene-expression changes.
Consistent signals
Bar length is a qualitative read of evidence strength at each rung, not a measured score.
Lab and animal studies: consistent signals. The 2026 evidence-mapping review in Pharmaceutics searched PubMed, Europe PMC, ClinicalTrials.gov and regulatory sources through August 2026. It found that "preclinical data consistently support effects on matrix remodeling, epithelial repair, inflammatory/redox regulation, and angiogenesis."
Small cosmetic studies in people: mixed. The same review calls historical cosmetic reports "small or incompletely characterized." In a 2006 randomized study of 13 patients after CO2 laser resurfacing, objective evaluation "found no significant improvement in wrinkles or overall skin quality" with GHK-Cu skincare, although patients using it reported higher satisfaction. The review also notes an 18-participant split-face eyebrow study in 2026 that reported positive cosmetic hair outcomes without defining the copper complex or local exposure.
Controlled wound trials: not yet a win. In a 1992 randomized, evaluator-blinded trial of 86 people with venous leg ulcers, a tripeptide copper complex cream performed no differently from an inert placebo, while silver sulfadiazine cream reduced ulcer size. A newer Phase 2 trial of a topical GHK-Cu gel on standardized skin wounds in healthy adults, NCT07437586, began in February 2026 and is recruiting. Its estimated primary completion is February 2027, and it has no results.
Approved drug: none.
A note on hair claims
GHK-Cu is often marketed for hair growth, usually citing a 2007 study on human hair follicles. That study tested AHK-Cu, a different copper tripeptide, on follicles in a dish, not GHK-Cu in people. It is interesting lab work. It is not evidence that GHK-Cu regrows hair. PeptIQ.io's GHK-Cu vs minoxidil explainer compares the two.
The review's bottom line is the fairest summary available: the clinical evidence "remains sparse and does not meet contemporary active-entity quality standards." It adds that formulation matters more than marketing admits: copper occupancy, stability and how much intact GHK-Cu is actually delivered are often not reported.
FDA Status in 2026
FDA status for GHK-Cu changed twice this spring, and many pages still describe it incorrectly. Here is the record from FDA's own documents.
03 / FDA status timeline
What changed in 2026
Two status changes in three weeks left many pages out of date. This is the record from FDA’s own documents.
Feb 2026
Phase 2 topical gel trial starts
NCT07437586, a randomized, vehicle-controlled split-wound study in healthy adults, begins recruiting.
Apr 22, 2026
Nominations withdrawn
GHK-Cu removed from category 1. FDA’s safety-risk page lists injectable GHK-Cu as nominated but withdrawn, citing immunogenicity and limited human data.
May 5, 2026
Nominator clarifies
One nominator says it meant to withdraw only the injectable route.
May 14, 2026
Non-injectable back in category 1
FDA’s updated list: “GHK-Cu (except for injectable routes of administration)” is under evaluation. Not approval.
By end of Feb 2027
Advisory committee consult
FDA intends to consult the PCAC on potential inclusion of GHK-Cu on the 503A bulks list.
Feb 2027 (est.)
Trial primary completion
Estimated primary completion for the Phase 2 gel trial. Results, if published, come later.
Dates from FDA’s 503A bulk drug substances list (updated May 14, 2026), FDA’s safety-risk page (current as of April 22, 2026) and ClinicalTrials.gov. Dashed markers are planned or estimated. Status checked October 22, 2026.
Nothing is approved. No FDA-approved drug contains GHK-Cu.
Non-injectable GHK-Cu is "under evaluation" for pharmacy compounding. FDA's 503A bulk drug substances list, updated May 14, 2026, shows that "GHK-Cu (except for injectable routes of administration)" was removed from category 1 on April 22, 2026 after the nominations were withdrawn. On May 5, one nominator clarified it meant to withdraw only the injectable route, so the non-injectable form "will be added back to category 1." Category 1 means a substance is under evaluation. It is not approval.
Injectable GHK-Cu was withdrawn, with safety concerns on record. Injectable GHK-Cu is not in category 1 or category 2. FDA's safety-risk page lists it among substances "nominated but withdrawn," with the immunogenicity and limited-human-data concerns quoted above.
An advisory committee review is planned. FDA "intends to consult the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027 regarding the potential inclusion of GHK-Cu on the 503A bulks list."
What this means for you: whether any pharmacy can compound a GHK-Cu product for you depends on these federal categories, state pharmacy rules and the route of administration. A pharmacist or prescribing clinician is the right person to explain your options. If you saw a headline saying GHK-Cu was "cleared" or "approved" for injection, it was wrong. PeptIQ.io's earlier April 2026 Category 2 explainer covers the background. The FDA documents above are the current record.
Safety and What We Don't Know
The honest answer for most safety questions is that the data does not exist yet.
Topical products: skin irritation is possible with any active cosmetic ingredient. Patch-test new products and stop if your skin reacts.
Injectable products: FDA's stated concerns are immune reactions linked to aggregation and impurities, plus limited human safety data. "Research use only" vials add identity, purity and sterility risks that no regulator checks. PeptIQ.io's source vetting checklist and COA reading guide explain what lab paperwork can and cannot tell you.
Blends: GHK-Cu appears in multi-peptide vials such as GLOW and KLOW. Each added compound adds its own unknowns. See the GLOW blend guide and KLOW blend guide.
Copper: GHK-Cu delivers copper. Whether that matters at the amounts people use has not been well studied in humans, which is one more reason to involve a clinician.
How to Read GHK-Cu Claims
Most GHK-Cu marketing borrows lab results and presents them as proven human benefits. Four questions cut through it:
Was it tested in people, or in cells and animals? Gene-expression and fibroblast studies are not outcome trials.
Was it topical or injected? Topical findings do not transfer to injection.
Was it GHK-Cu? Several studies cited for GHK-Cu tested related copper peptides or multi-ingredient products.
Was there a control group, and what was measured? Patient satisfaction and objective skin measurements can point in different directions, as the 2006 laser study showed.
PeptIQ.io's Peptide Claim Auditor takes a link to an Instagram, TikTok, X or Reddit post and checks each peptide claim in it against PubMed research. It is a fast way to test a GHK-Cu post before believing it.
Talk to a Licensed Clinician
A dermatologist is the right first stop for skin goals, and a prescribing clinician or pharmacist for anything injectable. Bring the product, its label and any lab paperwork. Ask whether it is a cosmetic or a drug, what the evidence is for your specific goal, and whether an approved treatment exists for it. If you already use a GHK-Cu product, tell your clinician, even if it is "just a serum." Report suspected adverse reactions to FDA MedWatch.
Frequently Asked Questions
Q: What is GHK-Cu?
A: A naturally occurring tripeptide (glycine, histidine, lysine) bound to copper. It is studied mainly for skin and wound repair, and it appears in cosmetics as copper tripeptide-1.
Q: Is GHK-Cu FDA approved?
A: No. No FDA-approved drug contains GHK-Cu. Topical copper peptide skincare is sold as a cosmetic, which does not need FDA premarket approval. As of FDA's May 14, 2026 list, non-injectable GHK-Cu is in category 1 ("under evaluation") for pharmacy compounding, and injectable GHK-Cu was withdrawn with FDA safety concerns on record.
Q: Is topical or injectable GHK-Cu better?
A: They answer different questions. The limited human data that exists is mostly topical and cosmetic. Injectable use has no controlled human efficacy trials, and FDA has flagged immunogenicity and limited human safety data for compounded injectable versions.
Q: Does GHK-Cu work for skin?
A: Lab studies consistently show effects on collagen and repair pathways, but human results are small and mixed. A 2026 systematic review called it "promising but unproven." A controlled Phase 2 wound-healing trial of a topical gel is still recruiting.
Q: Does GHK-Cu grow hair?
A: That hasn't been shown in people. The study most often cited tested a different copper peptide (AHK-Cu) on hair follicles in a lab dish. Talk to a dermatologist about approved hair-loss treatments.
Q: Is GHK-Cu the same as collagen?
A: No. Collagen is a large structural protein. GHK-Cu is a three-amino-acid signaling peptide studied for its effects on the cells that make collagen.
This article is educational content from PeptIQ.io. It is not medical advice. Talk with a licensed clinician before starting, stopping, or changing any peptide, medication, or injection practice.
For clinics: running peptide or GLP-1 programs for patients? See PeptIQ.io for providers: protocol templates, a patient app, and adherence tracking in one console.
